Diffuse large cell lymphomas: Identification of prognostic factors and validation of the international non-Hodgkin's Lymphoma Prognostic Index
Skarlos, Dimosthenis V.
Kosmidis, Paraskevas A.
Google Scholar check
MetadataΕμφάνιση πλήρους εγγραφής
Several clinical prognostic factors have been identified that predict treatment outcome in patients with diffuse large cell lymphomas. An International Non-Hodgkin's Lymphoma Prognostic Index (IPI) has been recently formulated. We tried to identify the clinical prognostic factors that predict treatment outcome in Greek patients with diffuse large cell lymphomas and validated the IPI in these patients. The possible prognostic variables for tumor response, relapse-free (RFS) and overall survival (OS) were analyzed in 239 consecutive patients treated with anthracycline-based chemotherapy regimens. In univariate analysis, factors associated with poor response were stages III-IV, performance status (PS) ≤ 2, spleen and bone marrow involvement, more than one extranodal site involved, increased lactate dehydrogenase (LDH) value, hemoglobin (Hb) 50 mm/h. Multivariate analysis identified stage, PS, more than one extranodal site involved, increased LDH level, and ESR > 50 mm/h as the factors more predictive of poor response. For RFS, multiple Cox analysis found stages III-IV and bone marrow involvement to be statistically significant. For OS, multiple Cox analysis identified stage III-IV, PS ≤ 2, bone marrow involvement, more than one extranodal site involved, increased LDH level and ESR > 50 mm/h as negative prognostic factors. Patients stratified in the different risk groups of the IPI had a significantly different outcome regarding complete response (CR) rate, RFS and OS. In conclusion, although age > 60 years was not recognized as an adverse factor in this analysis, our patients stratified in the different groups of the IPI had significant differences in CR rate, 2-year RFS and OS verifying the prognostic significance of the index. Bone marrow involvement and ESR > 50 mm/h, parameters that are not included in the IPI, adversely affected survival.
Showing items related by title, author, creator and subject.
Non-Hodgkin's Lymphomas in Greece according to the WHO classification of lymphoid neoplasms a retrospective analysis of 810 cases Economopoulos, T.; Papageorgiou, S.; Dimopoulos, M. A.; Pavlidis, Nicholas; Tsatalas, C.; Symeonidis, A.; Foudoulakis, A.; Pectasides, Dimitrios; Rontogianni, D.; Rizos, E.; Chalkia, P.; Anagnostopoulos, A.; Melachrinou, M.; Papageorgiou, E.; Fountzilas, George (2005)The purpose of this retrospective study, the largest unselected series in our country, was to illustrate the clinicopathological features of non-Hodgkin's lymphoma (NHL) classified according to the World Health Organization ...
Multifocal extranodal non-Hodgkin lymphoma: A clinicopathologic study of 37 cases in Greece, a Hellenic Cooperative Oncology Group Study Economopoulos, T.; Papageorgiou, S.; Rontogianni, D.; Kaloutsi, V.; Fountzilas, George; Tsatalas, C.; Pavlidis, Nicholas; Pectasides, Dimitrios; Papageorgiou, E.; Dimopoulos, M. A. (2005)The purpose of this retrospective study was to illustrate the clinicopathological features of patients presenting with multifocal extranodal non-Hodgkin lymphoma (NHL). Among 810 patients with NHL, 37 cases (4.2%) were ...
CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group Economopoulos, T.; Psyrri, A.; Dimopoulos, M. A.; Kalogera-Fountzila, Anna; Pavlidis, Nicholas; Tsatalas, C.; Nikolaides, C.; Mellou, S.; Xiros, N.; Fountzilas, George (2007)Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) ...